Vitrolife faces a tough start in 2025, and we expect this to continue during H1 2025. In short, Vitrolife is stepping up its investments in commercial capacity and sales during a period of softer organic growth. In Q1, the softer areas are the APAC regions and technologies, apart from pressure in OPEX and operating cash flow.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/